API | squalamine lactate

squalamine lactate Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Squalamine is a steroid-polyamine conjugate compound with broad spectrum antimicrobial activity and anti-angiogenic activity. It was studied as a potential cancer drug and as a potential treatment for wet macular degeneration but as of 2018 had not succeeded in Phase III trials for any use. ^Wikipedia

Chemistry

SMILES: O.CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(=O)(=O)O.C[C@H](O)C(=O)O
InChIKey: ZPYIELFRIYUVQP-BHBJEIPNSA-N
Mol. Mass: 736.07
ALogP: 5.55 Partition coefficient
ChEMBL Molecules:

squalamine lactate

None

More Chemistry

Pharmacology

Mechanism of Action:
- Sodium/hydrogen exchanger 3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

msi-1256f | squalamine lactate

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Macular Degeneration (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue